Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
16.40
-0.64 (-3.76%)
At close: Mar 13, 2026, 4:00 PM EDT
16.47
+0.07 (0.43%)
After-hours: Mar 13, 2026, 7:34 PM EDT
Sarepta Therapeutics Revenue
In the year 2025, Sarepta Therapeutics had annual revenue of $2.20B with 15.58% growth. Sarepta Therapeutics had revenue of $442.93M in the quarter ending December 31, 2025, a decrease of -32.73%.
Revenue (ttm)
$2.20B
Revenue Growth
+15.58%
P/S Ratio
0.78
Revenue / Employee
$2,632,619
Employees
835
Market Cap
1.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.20B | 296.26M | 15.58% |
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
| Dec 31, 2019 | 380.83M | 79.80M | 26.51% |
| Dec 31, 2018 | 301.03M | 146.45M | 94.74% |
| Dec 31, 2017 | 154.58M | 149.16M | 2,751.58% |
| Dec 31, 2016 | 5.42M | 4.17M | 332.64% |
| Dec 31, 2015 | 1.25M | -8.50M | -87.16% |
| Dec 31, 2014 | 9.76M | -4.46M | -31.38% |
| Dec 31, 2013 | 14.22M | -23.11M | -61.91% |
| Dec 31, 2012 | 37.33M | -9.66M | -20.56% |
| Dec 31, 2011 | 46.99M | 17.57M | 59.72% |
| Dec 31, 2010 | 29.42M | 11.84M | 67.30% |
| Dec 31, 2009 | 17.59M | -3.67M | -17.28% |
| Dec 31, 2008 | 21.26M | 10.27M | 93.52% |
| Dec 31, 2007 | 10.99M | 10.87M | 9,428.06% |
| Dec 31, 2006 | 115.29K | -4.67M | -97.59% |
| Dec 31, 2005 | 4.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.12B |
| AnaptysBio | 234.60M |
| Soleno Therapeutics | 190.41M |
| Zymeworks | 105.97M |
| Recursion Pharmaceuticals | 74.68M |
| Generate Biomedicines | 31.89M |
SRPT News
- 10 days ago - Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 14 days ago - Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program - Business Wire
- 15 days ago - Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress - Business Wire
- 15 days ago - Sarepta CEO To Jump Ship After 'Tumultuous' Year - Benzinga
- 15 days ago - Sarepta Therapeutics CEO Ingram to retire by year end - Reuters
- 16 days ago - Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments - Business Wire
- 17 days ago - Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan - Business Wire